Abstract
Daratumumab (Dara) is a monoclonal antibody against CD38 that has shown high efficacy and safety profile in relapsed multiple myeloma (MM) patients as single agent and in combination with other antimyeloma agents. It has recently approved for front-line therapy in patients ineligible for hematopoietic stem cell transplantation [1]. It is well recognized that Dara interferes with blood bank testing by binding to CD38 on red blood cells (RBC) and causing panagglutination in the Indirect Antiglobulin test (IAT).
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call